The primary purpose of this study is to assess the efficacy and safety of ruxolitinib 1.5% cream applied twice daily in participants with mild to moderate HS (Hurley Stage I or II) without draining tunnels.

Currently, there are no FDA-approved medications for the treatment of irritability associated with Autism Spectrum Disorder (ASD). This study is designed to look at the usefulness and safety of lumateperone (CAPLYTA) for the treatment of irritability associated with ASD among pediatric participants between the ages of 5 to 17 years. The study will last approximately 26 weeks and the participants will receive the study drug, lumateperone.

This phase 2 study is enrolling patients who have acute myeloid leukemia (AML) with certain biomarkers. This study is being done to see the effectiveness of different combinations of drugs to treat AML. It will involve 3 groups of patients receiving different combinations of Gilteritinib, Azacitidine and Venetoclax. Gilteritinib is an investigational drug, Azacitidine and Venetoclax are FDA approved. The main purpose of the study is to see if the amount of leukemia in the patient's body can be lowered by adding the drug Gilteritinib to the Standard of Care of treating AML with Azacitidine and Venetoclax. The study will include approximately 147 patients. The patients will be randomized into the three groups (like flipping a coin), Group 1 will receive just Azacitidine + Venetoclax, Groups 2 and 3 will also receive Gilteritinib but Group 2 will receive it for more time within a treatment cycle. Patients will complete screening after participating in this treatment trial or SOC therapies. Patients will continue treatment until disease progression, unacceptable toxicity, study closure, death, or withdrawal of consent. The main risk is that the study drugs may not be as good as the usual approach for their cancer or condition at shrinking or stabilizing their cancer. Patients may have none, some, or all of the side effects listed or not listed in the protocol, and they may be mild, moderate, or severe. There is no direct benefit for them in participating in this study.

This study is for patients that have been diagnosed with previously untreated, locally advanced, and metastatic pancreatic ductal adenocarcinoma PDAC. This study is testing two treatment regimens: NALIRIFOX (5-fluorouracil, liposomal irinotecan, oxaliplatin, and leucovorin) vs mGAP (gemcitabine, nab-paclitaxel, and cisplatin).
The primary purpose of this study is to see which of the two regimens is more effective in PDAC. Participants will continue on study medications if seeing clinical benefit, and can expect to be on the study for a maximum of 6 months.

This a blood draw study. Blood samples will be collected every 4 weeks on women diagnosed with fetal growth restriction. We hope it will help to determine other ways to evaluate patients with fetal growth restriction and thus improve outcomes.

To describe current real-world utilization of mcfDNA testing for CV infections using a multi-center retrospective registry. We will develop multi-center REDCap database of mcfDNA use in valvular IE and/or CIED lead infections and summarize patient demographics and clinical characteristics of IE and CIED lead infection cases. We will assess common scenarios/indications for which mcfDNA is sent and timing of the test. Clinically relevant microbiological yield of mcfDNA in IE and/or CIED lead infections will be described.

To identify clinical predictors where mcfDNA outperforms CMT. We will assess clinical characteristics of patients with IE and CIED lead infection in whom mcfDNA has higher microbiologic yield compared to CMT. We will develop a prediction model/scoring system to identify subgroup of patients in whom mcfDNA should be sent early (after 48 hours of negative CMT).

To analyze clinical impact of mcfDNA testing in patients with valvular IE and/or CIED lead infections. We will classify cases as having Positive vs. Negative vs. Neutral impact using pre-specified definitions and assess predictor of positive clinical impact.

This study is enrolling participants with heart failure, a condition where the heart muscle does not pump blood efficiently, with preserved ejection fraction, meaning the heart muscle contracts (squeezes) normally but is unable to relax appropriately. The study involves implanting a pacemaker, a small device that is placed in the upper left chest, and then programming it to either standard settings or personalized settings for you based on your height and heart function. The programming is randomized, meaning assigned by chance, like flipping a coin so you do not get to choose which group you are in nor does your doctor. The study is trying to determine if using the pacemaker to control your heart rate can help you heart failure.

Your participation will last at least 18 months and may be as long as 4.5 years depending on when you join the study. The study will include about 8 visits and include the pacemaker implant procedure as well as testing such as physical exams, 6 minute walk test, echocardiograms (ultrasound test of your heart), blood work, questionnaires and pacemaker checks.

There are risks associated with the pacemaker implant procedure, risks related to study related procedures and the risk of loss of confidentiality. There may be benefit to you and to others with this condition in the future.

This study is patients that have been diagnosed with high-risk renal cell carcinoma. This study will compare disease free survival (DFS) in patients treated with adjuvant pembrolizumab and tivozanib versus those receiving pembrolizumab alone. Participants can expect to remain in the study for 10years. There will be a total of 14 patient enrolled locally.

This study is looking for individuals who have resistant hypertension. This is a non-interventional research study and it does not involve a new drug or treatment. The goal of this study is to find out how many people with resistant hypertension, a type of high blood pressure that is hard to control, also have high levels of a hormone called cortisol. High cortisol levels, a condition called hypercortisolism, may make it more difficult to manage blood pressure. If you join the study, you will attend two to three clinic visits. During the first visit, you will go to the clinic for a short checkup. You will have vitals and your medical history reviewed. You will also have a blood draw and be given a pill called dexamethasone which will help us assess your cortisol levels. At your second visit you will fast and have a your blood collected to review your cortisol levels. If necessary, you will be invited for a third visit where you will get a CT scan. The risks associated with the study include bruising, dizziness, or, in rare cases, infection from blood draws, allergic reactions from taking the dexamethasone pill, and exposure to radiation from the CT scan. The study will be completed over the course of 2-3 visits in one months timeframe.

This phase 2 study is screening patients who may have acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). This study is a non-treatment protocol and the first step of taking part in myeloMATCH, which is a clinical trial. The main purpose of the study is to see if testing on patient's bone marrow and blood results in finding certain biomarkers that will qualify participants for the treatment study or for Standard of Care (SOC) therapies. The study will enroll approximately 5000 patients. The study has two periods, initial and post-treatment screening. It takes about four days for the study doctor to receive the screening results and the patient's first treatment assignment in myeloMATCH. Patients will complete post-treatment screening after their participation in treatment trials or SOC therapies. It will take about 11 days for the study doctor to receive these results and decide their next treatment assignment. Further testing may match patients with myeloMATCH substudies in the future. The main risk is that biomarker test results may be wrong. Patients may have none, some, or all of the side effects listed or not listed in the protocol, and they may be mild, moderate, or severe. There is no direct benefit for them in participating in this study.